Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Grüllich, C.; Rini, B. I.; Huseni, M.; Atkins, M.; McDermott, D.; Powles, T.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; Fan, J.; Doss, J.; Nalle, S.; Carroll, S.; Li, S.; Schiff, C.; Green, M.; Motzer, R. J. |
| Abstract Title: | Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 42 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2019 Oct 11-14 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2019-10-01 |
| Start Page: | 148 |
| Language: | English |
| ACCESSION: | WOS:000568159600359 |
| PROVIDER: | wos |
| DOI: | 10.1159/000502425 |
| Notes: | "Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology" -- Meeting Abstract: V552 -- Source: Wos |
